Literature DB >> 27346914

The challenge of costly drugs.

Charles Denaro1, Jennifer Martin2.   

Abstract

Keywords:  Pharmaceutical Benefits Scheme; cost-effectiveness of drugs; hepatitis C

Year:  2016        PMID： 27346914      PMCID： PMC4919167          DOI： 10.18773/austprescr.2016.037

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  5 in total

1.  Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study.

Authors:  Manfred Wiese; Kurt Grüngreiff; Wolfgang Güthoff; Michael Lafrenz; Ute Oesen; Heiner Porst
Journal:  J Hepatol       Date:  2005-10       Impact factor: 25.083

2.  The use of QALYs in clinical and patient decision-making: issues and prospects.

Authors:  Paul Kind; Jennifer Elston Lafata; Karl Matuszewski; Dennis Raisch
Journal:  Value Health       Date:  2009-03       Impact factor: 5.725

3.  Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Authors:  Ken J Harvey; Richard O Day; William G Campbell; Wendy Lipworth
Journal:  Med J Aust       Date:  2011-06-06       Impact factor: 7.738

4.  The $2.6 billion pill--methodologic and policy considerations.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

5.  What doctors should know about the Trans-Pacific Partnership Agreement.

Authors:  Anne Marie T Thow; Deborah H Gleeson; Sharon Friel
Journal:  Med J Aust       Date:  2015-03-02       Impact factor: 7.738
  5 in total
  1 in total

1.  The challenge of costly drugs.

Authors:  Nadine Hillock
Journal:  Aust Prescr       Date:  2016-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.